Novo Nordisk gains EU approval for broader use of two insulin analogues  

Healthcare company Novo Nordisk has gained extended marketing authorisation for Levemir and NovoRapid

Healthcare company Novo Nordisk has received EU approval for broader use of Levemir to include treatment of diabetes in children and adolescents from 6-17 years of age. Levemir is a long-acting insulin analogue that clinical trials have shown provides more consistent day-to-day control of blood glucose levels compared to conventional insulin preparations. Novo Nordisk also gained an extended marketing authorisation for NovoRapid to include treatment of diabetes in children from 2-6 years of age. NovoRapid is a rapid-acting insulin analogue which can be administered immediately before or after a meal.

Novo Nordisk is the first company to offer both a long-acting insulin analogue and a rapid-acting insulin analogue for the treatment of children with diabetes. The news is reported in a press release on the Novo Nordisk website.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest product portfolio in the industry, including advanced products in the area of insulin delivery systems. It also has a leading position in areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk is headquartered in Bagsværd, north of Copenhagen, and employs about 20,250 people in 78 countries.

Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×